


Should you consider using **BAMLANIVIMAB** to treat your COVID patient



IS YOUR PATIENT...



SARS-CoV-2
positive



12 years of age
or older



40 kg (88.2 lbs.)
or heavier



at high risk for
severe COVID-19




at high risk for
hospitalization

HIGH RISK PATIENTS ARE PATIENTS WHO...


- have a BMI greater than 35
- have chronic kidney disease
- have diabetes
- have immunosuppressive disease
- are currently receiving immunosuppressive treatment
- are 65 years of age or older
- are 55 years of age or older AND have...
 - cardiovascular disease OR
 - hypertension OR
 - chronic obstructive pulmonary disease (or other chronic respiratory disease)
- are 12 to 17 years of age AND have...
 - a BMI greater than the 85th percentile for their age and gender OR
 - sickle cell disease OR
 - congenital or acquired heart disease OR
 - neurodevelopmental disorders OR
 - a medical-related technological dependence (tracheostomy, gastrostomy, or positive pressure ventilation unrelated to COVID-19) OR
 - asthma, reactive airway, or other chronic respiratory disease requiring daily medication to control

**DO NOT use
BAMLANIVIMAB
if your patient...**

is already
hospitalized due
to COVID-19



requires oxygen
therapy due to
COVID-19



requires an increase in baseline oxygen
due to COVID-19 and is already on
chronic oxygen therapy due to underlying
comorbidities unrelated to COVID-19

WHAT ELSE DO YOU NEED TO KNOW?



BAMLANIVIMAB
has been authorized
by the FDA for
emergency use only




BAMLANIVIMAB
is authorized only
while emergency
use is justified



BAMLANIVIMAB
has not been
observed in patients
hospitalized due to
COVID-19



BAMLANIVIMAB
may adversely affect
clinical outcomes for
patients hospitalized
due to COVID-19



BAMLANIVIMAB must be administered by IV infusion where there is immediate access to medications that treat severe allergic reactions such as anaphylaxis and where EMS can be activated if necessary.

For more information on clinical trials of BAMLANIVIMAB visit
www.clinicaltrials.gov